Research
Hormonal
Myostatin acts as a negative regulator of muscle hypertrophy and cardiac pathological hypertrophy, and its inhibition or reduction through exercise can promote muscle growth and protect against certain cardiac dysfunctions.
Consistent exercise naturally lowers myostatin, a protein that limits muscle growth. This is one reason why regular resistance training is effective for building muscle.
ModerateQualifiesMEDIUM confidence
Consistent exercise reduces myostatin levels, and genetic deletion or pharmacological inhibition of myostatin enhances skeletal muscle hypertrophy... myostatin attenuates cardiac pathological hypertrophy in rats and in isolated cardiomyocytes.
Why this rating
The paper cites animal models and in vitro studies, with some conflicting data on clinical translation.
Source
Skeletal Muscle as a Mediator of Interorgan Crosstalk During Exercise: Implications for Aging and Obesity
Julia A. Pinette et al. · Circulation Research · 2025
DOI 10.1161/circresaha.124.325614
narrative_reviewCited 20×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Regular physical exercise prevents age-related skeletal muscle dysfunction, including loss of strength and mitochondrial capacity, by inducing structural remodeling and metabolic adaptations.Good
- Skeletal muscle releases myokines (such as Irisin and Myostatin) during exercise, which mediate interorgan crosstalk to improve metabolic health, regulate adipose tissue, and protect against cardiovascular disease.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →